Abstract
There are no wholly successful chemotherapeutic strategies against Burkholderia cepacia complex (BCC) colonization in cystic fibrosis (CF). We assessed the impact of cysteamine (Lynovex) in combination with standard-of-care CF antibiotics in vitro against BCC CF isolates by the concentration at which 100% of bacteria were killed (MIC100) and checkerboard assays under CLSI standard conditions. Cysteamine facilitated the aminoglycoside-, fluoroquinolone- and folate pathway inhibitor-mediated killing of BCC organisms that were otherwise resistant or intermediately sensitive to these antibiotic classes. Slow-growing BCC strains are often recalcitrant to treatment and form biofilms. In assessing the impact of cysteamine on biofilms, we demonstrated inhibition of BCC biofilm formation at sub-MIC100s of cysteamine.
Highlights
There are no wholly successful chemotherapeutic strategies against Burkholderia cepacia complex (BCC) colonization in cystic fibrosis (CF)
We previously described the antimicrobial, antibiofilm, and mucolytic attributes of cysteamine against Pseudomonas aeruginosa and other CF bacterial pathogens [10,11,12] and report here that, more strikingly, the modification of currently available therapeutic strategies [2, 13] with the introduction of cysteamine as an adjunct antimicrobial agent brings about effective killing of BCC
The 36 Burkholderia strains employed for this study include representative strains from each species, including B. cenocepacia and B. multivorans, those most commonly associated with infection in cystic fibrosis [14]
Summary
There are no wholly successful chemotherapeutic strategies against Burkholderia cepacia complex (BCC) colonization in cystic fibrosis (CF). If not all, BCC strains [5] are clinically resistant or inherently insensitive to currently available CF antibiotics [2, 6, 7]. We previously described the antimicrobial, antibiofilm, and mucolytic attributes of cysteamine against Pseudomonas aeruginosa and other CF bacterial pathogens [10,11,12] and report here that, more strikingly, the modification of currently available therapeutic strategies [2, 13] with the introduction of cysteamine as an adjunct antimicrobial agent brings about effective killing of BCC (both type strains and CF isolates)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
